Namita Goyal
A5049803861- Amyotrophic Lateral Sclerosis Research
- Inflammatory Myopathies and Dermatomyositis
- Neurogenetic and Muscular Disorders Research
- Myasthenia Gravis and Thymoma
- Peripheral Neuropathies and Disorders
- Muscle Physiology and Disorders
- Parkinson's Disease and Spinal Disorders
- Eosinophilic Disorders and Syndromes
- Parkinson's Disease Mechanisms and Treatments
- Glycogen Storage Diseases and Myoclonus
- Immunodeficiency and Autoimmune Disorders
- Muscle and Compartmental Disorders
- Hereditary Neurological Disorders
- Genetic Neurodegenerative Diseases
- Cholinesterase and Neurodegenerative Diseases
- Lysosomal Storage Disorders Research
- Alzheimer's disease research and treatments
- Cardiomyopathy and Myosin Studies
- Muscle activation and electromyography studies
- Nerve injury and regeneration
- Peripheral Nerve Disorders
- Systemic Sclerosis and Related Diseases
- Prion Diseases and Protein Misfolding
- Biochemical and Molecular Research
- Cerebral Palsy and Movement Disorders
University of California, Irvine Medical Center
2020-2025
University of Missouri
2025
University of California, Irvine
2015-2024
Rabindranath Tagore Medical College
2015-2024
UC Irvine Health
2018-2024
Maharaja Engineering College
2022-2024
Rajasthan University of Health Sciences
2023
Maastricht University Medical Centre
2023
University of Kansas Medical Center
2016-2022
Columbia University
2022
Sodium phenylbutyrate and taurursodiol have been found to reduce neuronal death in experimental models. The efficacy safety of a combination the two compounds persons with amyotrophic lateral sclerosis (ALS) are not known.
<h3>Objective:</h3> To study activin signaling and its blockade in sporadic inclusion body myositis (sIBM) through translational studies a randomized controlled trial. <h3>Methods:</h3> We measured transforming growth factor β by SMAD2/3 phosphorylation muscle biopsies of 50 patients with neuromuscular disease (17 sIBM). tested inhibition receptors IIA IIB (ActRII) 14 sIBM using one dose bimagrumab (n = 11) or placebo 3). The primary outcome was the change right thigh volume MRI at 8 weeks....
Abstract An orally administered, fixed‐dose coformulation of sodium phenylbutyrate‐taurursodiol (PB‐TURSO) significantly slowed functional decline in a randomized, placebo‐controlled, phase 2 trial ALS (CENTAUR). Herein we report results long‐term survival analysis participants CENTAUR. In CENTAUR, adults with were randomized 2:1 to PB‐TURSO or placebo. Participants completing the 6‐month (24‐week) eligible receive open‐label extension. all‐cause mortality (35‐month maximum follow‐up...
Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated.
Electrical impedance myography (EIM), a non-invasive, electrophysiological technique, has preliminarily shown value as an ALS biomarker. Here we perform multicenter study to further assess EIM’s potential for tracking ALS. patients were enrolled across eight sites. Each subject underwent EIM, handheld dynamometry (HHD), and the Functional Rating Scale-revised (ALSFRS-R) regularly. Techniques compared by assessing coefficient of variation (CoV) in rate decline each technique’s correlation...
Mutations in valosin-containing protein (VCP), an ATPase involved degradation and autophagy, cause VCP disease, a progressive autosomal dominant adult onset multisystem proteinopathy. The goal of this study is to examine if phenotypic differences disorder could be explained by the specific gene mutations. We therefore studied 231 individuals (118 males 113 females) from 36 families carrying 15 different analyzed correlation between mutations prevalence, age severity myopathy, Paget's disease...
To determine the steroid-sparing effect of methotrexate (MTX) in patients with symptomatic generalized myasthenia gravis (MG).We performed a 12-month multicenter, randomized, double-blind, placebo-controlled trial MTX 20 mg orally every week vs placebo 50 acetylcholine receptor antibody-positive MG between April 2009 and August 2014. The primary outcome measure was prednisone area under dose-time curve (AUDTC) from months 4 to 12. Secondary measures included changes Quantitative Myasthenia...
<h3>Objective</h3> To investigate the efficacy and safety of belimumab, a fully human immunoglobulin G1λ monoclonal antibody against B-lymphocyte stimulator, in participants with generalized myasthenia gravis (MG) who remained symptomatic despite standard care (SoC) therapy. <h3>Methods</h3> Eligible MG were randomized 1:1 to receive IV belimumab 10 mg/kg or placebo this phase II, placebo-controlled, multicenter, double-blind study (NCT01480596; BEL115123). Participants received SoC...
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the motor nervous system. Clinical studies have demonstrated cortical and spinal neuron hyperexcitability using transcranial magnetic stimulation threshold tracking nerve conduction studies, respectively, although metrics excitability not been used as pharmacodynamic biomarkers in multi-site clinical trials.To ascertain whether ezogabine decreases ALS.This double-blind, placebo-controlled phase 2 randomized...
<h3>Objectives</h3> To explore phenotypic differences between individuals with sporadic inclusion body myositis (sIBM) who are seropositive for the NT5c1A antibody compared those seronegative. <h3>Methods</h3> Cross-sectional clinical, serological and functional analysis in 25 consecutive participants sIBM. <h3>Results</h3> All met criteria clinically defined or probable 18 of sIBM (72%) were antibody. No median age duration illness two groups seen. Females have higher odds being (OR=2.30)....
Abstract Introduction/Aims Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative illness with great unmet patient need. We aimed to evaluate whether mesenchymal stem cells induced secrete high levels of neurotrophic factors (MSC‐NTF), novel autologous cell‐therapy capable targeting multiple pathways, could safely slow ALS disease progression. Methods This randomized, double‐blind, placebo‐controlled study enrolled participants meeting revised El Escorial criteria, Functional...
Coformulated sodium phenylbutyrate/taurursodiol (PB/TURSO) was shown to prolong survival and slow functional decline in amyotrophic lateral sclerosis (ALS).
<h3>Objective</h3> To define the current treatment practice of Guillain-Barré syndrome (GBS). <h3>Methods</h3> The study was based on prospective observational data from first 1,300 patients included in International GBS Outcome Study. We described general, and for (1) severe forms (unable to walk independently), (2) no recovery after initial treatment, (3) treatment-related fluctuations, (4) mild (able (5) variant including Miller Fisher syndrome, taking patient characteristics hospital...
<h3>Background and Objectives</h3> To evaluate the therapeutic potential of targeting highly differentiated T cells in patients with inclusion body myositis (IBM) by establishing high-resolution mapping killer cell lectin-like receptor subfamily G member 1 (KLRG1<sup>+</sup>) within natural (NK) compartments. <h3>Methods</h3> Blood was collected from 51 IBM 19 healthy age-matched donors. Peripheral blood mononuclear were interrogated flow cytometry using a 12-marker antibody panel. The panel...
Electrical impedance myography (EIM) can be used to assess amyotrophic lateral sclerosis (ALS) progression. The relationship between EIM values and standard assessment measures, however, is unknown.EIM 50 kHz phase data from 60 subjects who participated in a longitudinal natural history study of ALS were correlated with handheld dynamometry (HHD), the Functional Rating Scale-Revised (ALSFRS-R) score, motor unit number estimation (MUNE).Moderate strength correlations parameters HHD observed...
Polyneuropathy signs (Neuropathy Impairment Score, NIS), neurophysiologic tests (m+7Ionis ), disability, and health scores were assessed in baseline evaluations of 100 patients entered into an oligonucleotide familial amyloidotic polyneuropathy (FAP) trial.We assessed: (1) Proficiency grading neurologic correlation with tests, (2) clinometric performance modified NIS+7 (mNIS+7Ionis ) its subscores disability scores.The mNIS+7Ionis sensitively detected, characterized, broadly scaled diverse...
Objective To evaluate safety, dose response, and preliminary efficacy of reldesemtiv over 12 weeks in patients with amyotrophic lateral sclerosis (ALS). Methods: Patients (≤2 years since diagnosis) slow upright vital capacity (SVC) ≥60% were randomized 1:1:1:1 to 150, 300, or 450 mg twice daily (bid) placebo; active treatment was 4-week follow-up. Primary endpoint change percent predicted SVC at weeks; secondary measures included ALS Functional Rating Scale-Revised (ALSFRS-R) muscle strength...
<h3>Objective</h3> To assess long-term (2 years) effects of bimagrumab in participants with sporadic inclusion body myositis (sIBM). <h3>Methods</h3> Participants (aged 36–85 who completed the core study (RESILIENT [Efficacy and Safety Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility sIBM Patients]) were invited to join an extension study. Individuals continued same treatment as (10 mg/kg, 3 1 mg/kg or matching placebo administered IV infusions every 4 weeks)....
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with motor neuron loss as defining feature. Despite significant effort, therapeutic breakthroughs have been modest. MN-166 (ibudilast) has demonstrated neuroprotective action by various mechanisms: inhibition of proinflammatory cytokines and macrophage migration inhibitory factor, phosphodiesterase inhibition, attenuation glial cell activation in models ALS. Early-phase studies suggest that may improve survival outcomes slow...
Multiple novel therapies have been approved for patients with myasthenia gravis. Our aim is to describe the early experience of efgartigimod use in acetylcholine receptor antibody-positive generalized gravis (AChR+ve gMG).This multicenter retrospective study included AChR+ve gMG from five major neuromuscular centers who were treated and had both pre- post-efgartigimod activities daily living (MG-ADL) scores. Information regarding MG history, concomitant treatment(s), MG-ADL other MG-specific...